Results 191 to 200 of about 96,828 (293)

Correction to "Sprouty2 Suppresses Progression and Correlates to Favourable Prognosis of Intrahepatic Cholangiocarcinoma via Antagonizing FGFR2 Signalling". [PDF]

J Cell Mol Med
europepmc   +1 more source

Saikosaponin D Induced Apoptosis and Anti-Tumor Effect Enhancing Chemotherapy Sensitivity of Gemcitabine in Patient-Derived Cholangiocarcinoma Organoids. [PDF]

Cancer Manag Res
Han B, Xing G, Du K, Li Y, Liu M, Zheng J, Wang S, Li C, Zhang S, Zhang C, Liu X, Shao Z, Wu W.   +12 more
europepmc   +1 more source

Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin‐1‐Mediated PI3K/AKT Signaling Pathway in Cisplatin‐Resistant Cervical Cancer Cells

The FASEB Journal, Volume 40, Issue 9, 15 May 2026.
Simvastatin synergizes with cisplatin in cisplatin‐resistant cervical cancer cells through suppression of the caveolin‐1‐mediated PI3K/AKT signaling axis. ABSTRACT Cervical cancer treatment is often hindered by the emergence of cisplatin (DDP) resistance. Increasing evidence has indicated that statins possess anti‐tumor and chemosensitization potential
Yujia Zhou, Hejing Liu, Shuangjia Pan, Luyi Ruan, Jiayi Ruan, Jiaru Chen, Huihui Ji, Xueqiong Zhu   +7 more
wiley   +1 more source

Epidemiologic transition of biliary tract cancers in an endemic region of Korea: insights from a regional cancer center cohort. [PDF]

BMC Gastroenterol
Jang A, Lee J.
europepmc   +1 more source

Proximal cholangiocarcinomas

Journal of British Surgery, 1988
openaire   +2 more sources

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

Molecular Oncology, Volume 20, Issue 5, Page 1299-1322, May 2026.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova   +10 more
wiley   +1 more source

Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301. [PDF]

ESMO Open
Abou-Alfa GK, Borbath I, Roychowdhury S, Goyal L, Lamarca A, Macarulla T, Shroff RT, Oh DY, Tamaş C, Savastano DM, van Veenhuyzen DF, Xu C, Freas E, Solanas J, Javle MM.   +14 more
europepmc   +1 more source

Cholangiocarcinoma and sclerosing cholangitis: clinical characteristics and effect on survival after liver transplantation. [PDF]

, 1993
Abu-Elmagd, KM, Baddour, N, Demetris, AJ, Fung, J, Irish, W, Iwatsuki, S, Selby, R, Starzl, TE, Todo, S, Tzakis, A, Van Thiel, DH   +10 more
core  

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

Advanced Science, Volume 13, Issue 25, 4 May 2026.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen, Yang Yu, Xiutao Cai, Junhao Lin, Ruirui Liang, Rui Kang, Daolin Tang, Jiao Liu   +7 more
wiley   +1 more source

27-Hydroxycholesterol in bile duct tissue promotes cholangiocarcinoma progression through estrogen receptor signaling. [PDF]

Am J Cancer Res
Konishi N, Miyazaki T, Shimoda M, Morishita Y, Honda A, Ikegami T, Suzuki S.   +6 more
europepmc   +1 more source